[go: up one dir, main page]

AR128074A1 - Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales - Google Patents

Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales

Info

Publication number
AR128074A1
AR128074A1 ARP220103558A ARP220103558A AR128074A1 AR 128074 A1 AR128074 A1 AR 128074A1 AR P220103558 A ARP220103558 A AR P220103558A AR P220103558 A ARP220103558 A AR P220103558A AR 128074 A1 AR128074 A1 AR 128074A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
animals
injectable pharmaceutical
respiratory diseases
Prior art date
Application number
ARP220103558A
Other languages
English (en)
Inventor
Chen Wang
- Meyer Thorsten Chao
Ralf Warrass
Joachim Ullrich
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR128074A1 publication Critical patent/AR128074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica inyectable para el tratamiento de una infección bacteriana en un animal, que comprende una cantidad eficaz de un compuesto de fórmula (1); o una de sus sales, y un portador farmacéuticamente aceptable, donde la composición inyectable es tanto eficaz como segura.
ARP220103558A 2021-12-24 2022-12-22 Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales AR128074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21217704 2021-12-24

Publications (1)

Publication Number Publication Date
AR128074A1 true AR128074A1 (es) 2024-03-20

Family

ID=79601675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103558A AR128074A1 (es) 2021-12-24 2022-12-22 Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales

Country Status (9)

Country Link
US (1) US20250057790A1 (es)
EP (1) EP4452226A1 (es)
JP (1) JP2024544415A (es)
CN (1) CN118632684A (es)
AR (1) AR128074A1 (es)
AU (1) AU2022420882A1 (es)
CA (1) CA3242451A1 (es)
MX (1) MX2024007862A (es)
WO (1) WO2023118557A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025133088A1 (en) 2023-12-21 2025-06-26 Intervet International B.V. Crystalline forms of(s)-n-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4- ((4-(((2-methoxyethyl)amino)methyl)phenyl)ethynyl)benzamide salts
WO2025133098A2 (en) 2023-12-21 2025-06-26 Intervet International B.V. Processes to make crystalline forms of (s)-n-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4- ((4-(((2-methoxyethyl)amino)methyl)phenyl)ethynyl)benzamide salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
BR112019012861A2 (pt) 2016-12-23 2019-12-10 Intervet Int Bv compostos para o tratamento de doença respiratória bovina ou suína

Also Published As

Publication number Publication date
JP2024544415A (ja) 2024-11-29
CA3242451A1 (en) 2023-06-29
WO2023118557A1 (en) 2023-06-29
AU2022420882A1 (en) 2024-06-20
EP4452226A1 (en) 2024-10-30
MX2024007862A (es) 2024-07-09
US20250057790A1 (en) 2025-02-20
CN118632684A (zh) 2024-09-10

Similar Documents

Publication Publication Date Title
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
UA92746C2 (en) Thiazole compounds and methods of use
AR128074A1 (es) Composición farmacéutica inyectable para el tratamiento de enfermedades respiratorias en animales
DOP2010000166A (es) Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales
HN2000000115A (es) Formulacion de sal comun y moxifloxacina
ECSP22091313A (es) Compuestos heterocíclicos como anthelmínticos
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
ECSP22036502A (es) Inhibidores del factor d del complemento para administraci?n oral
CO2022015630A2 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CL2025001080A1 (es) Método para preparar maribavir.
AR120931A1 (es) Fungicidas para prevenir y controlar patógenos fúngicos
CL2024002500A1 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
BR9908452A (pt) Composição fungicida que compreende uma benzoilfeniluréia
AR125388A1 (es) Compuestos para modular el glp-1r